AIPM · Analysis of protein misfolding as a pathogenetic mechanism in autoinflammatory diseases
FP7 — People (Marie Curie Actions)
- Duration
- 2011-04-01 → 2015-03-31
- EU contribution
- €100,000
- Participants
- 1
- Scheme
- MC-IRG
Lines connect the coordinator with its partners.
Results in brief
Periodic Report Summary - AIPM (Analysis of protein misfolding as a pathogenetic mechanism in autoinflammatory diseases)
Autoinflammatory diseases (AID) are an emerging group of mainly inherited disorders that lead to an innate immune dysregulation of cytokines. The common features are recurrent episodes of inflammation with fever. Systemic amyloidosis is the primary long-term morbidity, while treatment options are scarce. Thus, AID are associated with chronic disability and a significant impact on the health care system. Current data suggest protein misfolding with loss-of-function as a missense-induced principle in the monogenetic AID tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS), and mevalonate kinase deficiency (MKD). The objective of this project was to systematically elucidate the molecular mechanisms underlying MKD. Following cloning of the wild-type (WT) and mutant target protein mevalonate kinase (MK), successful prokaryotic expression and purification of mutant MK supports the hypothesis of protein misfolding in MKD that will be further evaluated by means of analysis of conformation and stability of the mutant protein. These results will then allow to set the ground for future targeted therapies in MKD.
Data: CORDIS, © European Union
Project objective
Autoinflammatory diseases (AID) are an emerging group of mainly inherited disorders that lead to an innate immune dysregulation of cytokines. The common features are recurrent episodes of inflammation with fever. Systemic amyloidosis is the primary long-term morbidity, while treatment options are scarce. Thus, AID are associated with chronic disability and a significant impact on the health care system. Current data suggest protein misfolding with loss-of-function as a missense-induced principle in three monogenetic AID: tumor necrosis factor receptor-1 associated periodic syndrome, hyperimmunoglobulinemia D with periodic fever syndrome, and familial Mediterranean fever. The objective of this project is therefore to systematically elucidate the molecular mechanisms underlying these AID with the ultimate goal to develop targeted therapeutic strategies. A high-end technological platform will be used to analyze conformation, stability and function of the three mutant proteins TNFRSF1A, mevalonate kinase and pyrin. Analyses will be supplemented by the investigation of the effect of compound heterozygosity and digenity on protein misfolding. Protein-protein interaction (PPI) partners will be analyzed by the automated bioluminescence resonance energy transfer (BRET) technology for detection of PPI in living cells, thus allowing for an in-depth functional understanding of the target proteins. A hypothesis driven approach will be established to identify candidate compounds with potential protein-stabilizing properties followed by experimental validation of the chaperone effect. This innovative, translational approach sets the ground for future targeted therapies in AID. The project also will help to reintegrate a well-recognized physician-scientist with substantial clinical and scientific expertise in AID in Germany, thereby significantly increasing European excellence, while simultaneously supporting a lasting co-operation with the United States.
Original text from CORDIS.
Participants
- LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN · PlaneggCoordinatorGermany
Links
Data: CORDIS, © European Union